⚫ Powered with Sitagliptin which is a FDA approved DDP-IV inhibitor that increases insulin release and decreases glucagen level in blood
⚫ Sitagliptin and Metformin provided substantil and additive glycemic improvement and was generally well tolerated in patients
⚫ Provides substantial and sustained Glycemic improvements and are well-tolerated
⚫ Sitagliptin alone and in combination with Metformin for more than 6 months has improved body weight and body mass index reduction.